Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies

Blood

Volumn 119, Issue 5, 2012, Pages 1318-1319

  Kroeze, Leonie I ^a   Nikoloski, Gorica ^a   Da Silva Coelho, Pedro ^a   Van Hoogen, Patricia ^a   Stevens Linders, Ellen ^a   Kuiper, Roland P ^a   Schnittger, Susanne ^b   Haferlach, Torsten ^b   Pahl, Heike L ^c   Van Der Reijden, Bert A ^a   Jansen, Joop H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; HISTONE METHYLTRANSFERASE; TRANSCRIPTION FACTOR EZH2;

BONE MARROW; CHRONIC MYELOMONOCYTIC LEUKEMIA; EMBRYONIC STEM CELL; ENZYME ACTIVITY; EPIGENETICS; FRAMESHIFT MUTATION; GENE DELETION; GENE MUTATION; GENE SILENCING; GENETIC DISORDER; GENETIC VARIABILITY; HEMATOPOIESIS; HUMAN; INFORMED CONSENT; LETHALITY; LETTER; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE;

EID: 84856623134     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-365213     Document Type: Letter

References (7)

1. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42(8):722-726.
2. Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42(8):665-667.
3. Makishima H, Jankowska AM, Tiu RV, et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia. 2010;24(10):1799-1804.
4. Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J. 2004;23(20):4061-4071. (Pubitemid 39472427)
5. Shen X, Liu Y, Hsu YJ, et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell. 2008;32(4):491-502.
6. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009;41(7):838-842.
7. Pasini D, Cloos PA, Walfridsson J, et al. JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells. Nature. 2010;464(7286):306-310.